165 related articles for article (PubMed ID: 30587908)
21. Efficacy of Once-Daily Ophthalmic Bilastine for the Treatment of Allergic Conjunctivitis: A Dose-Finding Study.
Gomes PJ; Ciolino JB; Arranz P; Hernández G; Fernández N
J Investig Allergol Clin Immunol; 2023 Jul; 33(4):271-280. PubMed ID: 35234641
[TBL] [Abstract][Full Text] [Related]
22. Comparison of the efficacy of combined fluticasone propionate and olopatadine versus combined fluticasone propionate and fexofenadine for the treatment of allergic rhinoconjunctivitis induced by conjunctival allergen challenge.
Lanier BQ; Abelson MB; Berger WE; Granet DB; D'Arienzo PA; Spangler DL; Kägi MK
Clin Ther; 2002 Jul; 24(7):1161-74. PubMed ID: 12182260
[TBL] [Abstract][Full Text] [Related]
23. A comparison of the relative clinical efficacy of a single dose of ketotifen fumarate 0.025% ophthalmic solution versus placebo in inhibiting the signs and symptoms of allergic rhinoconjunctivitis as induced by the conjunctival allergen challenge model.
Crampton HJ
Clin Ther; 2002 Nov; 24(11):1800-8. PubMed ID: 12501875
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model.
Berdy GJ; Stoppel JO; Epstein AB
Clin Ther; 2002 Jun; 24(6):918-29. PubMed ID: 12117082
[TBL] [Abstract][Full Text] [Related]
25. A placebo-controlled comparison of ketotifen fumarate and nedocromil sodium ophthalmic solutions for the prevention of ocular itching with the conjunctival allergen challenge model.
Greiner JV; Minno G
Clin Ther; 2003 Jul; 25(7):1988-2005. PubMed ID: 12946546
[TBL] [Abstract][Full Text] [Related]
26. Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model.
Abelson MB; Greiner JV
Curr Med Res Opin; 2004 Dec; 20(12):1953-8. PubMed ID: 15701212
[TBL] [Abstract][Full Text] [Related]
27. Bepotastine besilate ophthalmic solution 1.5% for alleviating nasal symptoms in patients with allergic conjunctivitis.
Cavet ME; Gomes PJ; Carr WW; Williams JI
J Asthma Allergy; 2018; 11():29-39. PubMed ID: 29615844
[TBL] [Abstract][Full Text] [Related]
28. Pooled analysis of two studies evaluating efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis.
McLaurin E; Bergmann M; Narvekar A; Adewale A; Gomes P; Torkildsen G
Clin Ophthalmol; 2017; 11():1089-1097. PubMed ID: 28652694
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of olopatadine ophthalmic solution 0.2% in reducing signs and symptoms of allergic conjunctivitis.
Abelson MB; Gomes PJ; Pasquine T; Edwards MR; Gross RD; Robertson SM
Allergy Asthma Proc; 2007; 28(4):427-33. PubMed ID: 17883910
[TBL] [Abstract][Full Text] [Related]
30. Exacerbation of signs and symptoms of allergic conjunctivitis by a controlled adverse environment challenge in subjects with a history of dry eye and ocular allergy.
Gomes PJ; Ousler GW; Welch DL; Smith LM; Coderre J; Abelson MB
Clin Ophthalmol; 2013; 7():157-65. PubMed ID: 23378734
[TBL] [Abstract][Full Text] [Related]
31. Emedastine ophthalmic solution 0.05% versus levocabastine ophthalmic suspension 0.05% in the treatment of allergic conjunctivitis using the conjunctival allergen challenge model.
Netland PA; Leahy C; Krenzer KL
Am J Ophthalmol; 2000 Dec; 130(6):717-23. PubMed ID: 11124289
[TBL] [Abstract][Full Text] [Related]
32. Phase 3 Randomized Study of Efficacy and Safety of a Dexamethasone Intracanalicular Insert in Patients With Allergic Conjunctivitis.
McLaurin EB; Evans D; Repke CS; Sato MA; Gomes PJ; Reilly E; Blender N; Silva FQ; Vantipalli S; Metzinger JL; Gibson A; Goldstein MH
Am J Ophthalmol; 2021 Sep; 229():288-300. PubMed ID: 33773984
[TBL] [Abstract][Full Text] [Related]
33. Bilastine 0.6% preservative-free eye drops, an effective once-daily treatment to reduce signs and symptoms of allergic conjunctivitis: A pooled analysis of two randomized clinical trials.
Gomes PJ; Ciolino JB; Arranz P; Gonzalo A; Fernández N; Hernández G
J Investig Allergol Clin Immunol; 2023 Sep; ():0. PubMed ID: 37732873
[TBL] [Abstract][Full Text] [Related]
34. Integrated phase III trials of bepotastine besilate ophthalmic solution 1.5% for ocular itching associated with allergic conjunctivitis.
Meier EJ; Torkildsen GL; Gow JA; McNamara TR; Gomes PJ; Williams JI;
Allergy Asthma Proc; 2012; 33(3):265-74. PubMed ID: 22991696
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of comfort using olopatadine hydrochloride 0.1% ophthalmic solution in the treatment of allergic conjunctivitis in contact lens wearers compared to placebo using the conjunctival allergen-challenge model.
Brodsky M; Berger WE; Butrus S; Epstein AB; Irkec M
Eye Contact Lens; 2003 Apr; 29(2):113-6. PubMed ID: 12695716
[TBL] [Abstract][Full Text] [Related]
36. A randomized, double-blind, parallel-group comparison of olopatadine 0.1% ophthalmic solution versus placebo for controlling the signs and symptoms of seasonal allergic conjunctivitis and rhinoconjunctivitis.
Abelson MB; Turner D
Clin Ther; 2003 Mar; 25(3):931-47. PubMed ID: 12852709
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%.
Greiner JV; Edwards-Swanson K; Ingerman A
Clin Ophthalmol; 2011 Jan; 5():87-93. PubMed ID: 21339800
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of desloratadine on conjunctival allergen challenge-induced ocular symptoms.
Torkildsen GL; Gomes P; Welch D; Gopalan G; Srinivasan S
Clin Exp Allergy; 2009 Jul; 39(7):1052-9. PubMed ID: 19302250
[TBL] [Abstract][Full Text] [Related]
39. Safety of cetirizine ophthalmic solution 0.24% for the treatment of allergic conjunctivitis in adult and pediatric subjects.
Malhotra RP; Meier E; Torkildsen G; Gomes PJ; Jasek MC
Clin Ophthalmol; 2019; 13():403-413. PubMed ID: 30858690
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0.1% ophthalmic solution and nedocromil sodium 2% ophthalmic solution in the human conjunctival allergen challenge model.
Butrus S; Greiner JV; Discepola M; Finegold I
Clin Ther; 2000 Dec; 22(12):1462-72. PubMed ID: 11192137
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
